公开(公告)号：US09901629B2

公开(公告)日：2018-02-27

申请号：US15638786

申请日：2017-06-30

申请人： IMMATICS BIOTECHNOLOGIES GMBH

发明人： Annika Sonntag ,  Toni Weinschenk ,  Andrea Mahr ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC分类号： A61K6/00 ,  A61K35/00 ,  A61K35/12 ,  A61K39/00

CPC分类号： C07K14/70539 ,  A61K35/17 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/70539 ,  G06F19/20

摘要： A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.